Results 21 to 30 of about 1,437,202 (311)

Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report

Therapeutic Drug Monitoring, 2019
: Ten years ago, a consensus report on the optimization of tacrolimus was published in this journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicity (IATDMCT)
M. Brunet, T. van Gelder, A. Åsberg, V. Haufroid, D. Hesselink, L. Langman, F. Lemaitre, P. Marquet, C. Seger, M. Shipkova, A. Vinks, P. Wallemacq, E. Wieland, J. Woillard, M. Barten, K. Budde, H. Colom, M. Dieterlen, L. Elens, K. Johnson-Davis, P. Kunicki, I. Macphee, S. Masuda, B. Mathew, O. Millán, T. Mizuno, D. Moes, C. Monchaud, Ofelia Noceti, T. Pawiński, N. Picard, R. V. van Schaik, C. Sommerer, N. T. Vethe, B. D. de Winter, U. Christians, S. Bergan   +36 more
semanticscholar   +1 more source

Role of therapeutic drug monitoring in pulmonary infections : use and potential for expanded use of dried blood spot samples [PDF]

, 2015
Respiratory tract infections are among the most common infections in men. We reviewed literature to document their pharmacological treatments, and the extent to which therapeutic drug monitoring (TDM) is needed during treatment.
Akkerman, Onno W, Alffenaar, Jan-Willem C, Bolhuis, Mathieu S, Hofman, Susan, Koster, Remco A, Stove, Christophe, van Assen, Sander   +6 more
core   +7 more sources

Optimal Practice for Vancomycin Therapeutic Drug Monitoring: Position Statement From the Anti-infectives Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

Therapeutic Drug Monitoring, 2021
: Individualization of vancomycin dosing based on therapeutic drug monitoring (TDM) data is known to improve patient outcomes compared with fixed or empirical dosing strategies.
S. Reuter, S. Stocker, J. Alffenaar, S. Baldelli, D. Cattaneo, Graham R D Jones, B. Koch, D. Kocic, Sumith K. Mathew, M. Molinaro, M. Neely, I. Sandaradura, D. Marriott   +12 more
semanticscholar   +1 more source

Clinical proteomics for precision medicine: the bladder cancer case [PDF]

, 2017
Precision medicine can improve patient management by guiding therapeutic decision based on molecular characteristics. The concept has been extensively addressed through the application of –omics based approaches.
Frantzi, Maria, Latosinska, Agnieszka, Merseburger, Axel S., Mischak, Harald, Vlahou, Antonia   +4 more
core   +1 more source

Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

Therapeutic Drug Monitoring, 2021
Purpose: Reduced exposure to echinocandins has been reported in specific patient populations, such as critically ill patients; however, fixed dosing strategies are still used.
H. Kim, S. Baldelli, A. Märtson, S. Stocker, J. Alffenaar, D. Cattaneo, D. Marriott   +6 more
semanticscholar   +1 more source

Therapeutic drug monitoring (TDM) of atazanavir in pregnancy [PDF]

, 2012
Purpose of the study: Pregnant women experience physiological changes during pregnancy resulting in clinically significant alterations in antiretroviral pharmacokinetics (PK).
D Back, J Breiden, J Lambert, L Else, M Brennan, M Lawless, S Coulter Smith, S Khoo, V Jackson   +8 more
core   +1 more source

Medication Complications in Extracorporeal Membrane Oxygenation. [PDF]

, 2017
The need for extracorporeal membrane oxygenation (ECMO) therapy is a marker of disease severity for which multiple medications are required. The therapy causes physiologic changes that impact drug pharmacokinetics.
Aebi, Ami G. Shah, Anderson, Arlt, Barr, Barthelemy, Beiderlinden, Bein, Bembea, Bhatt-Meht, Boucher, Brandi N. Thoma, Brown, Buck, Buscher, Chung, Dagan, Dagan, de Montmollin, De Rosa, DeGrado, Donadello, Donadello, Dzierba, Erstad, Esper, Eyler, Flordelis Lasierra, Glauber, Greenberg, Gélisse, Hadidi, Hertzog, Hraiech, Hynynen, Johnston, Kawada, Kim, Koster, Krueger, Lamarche, Latronico, Lemaitre, Levison, Malfertheiner, Mehta, Michelle Peahota, Moore, Mousavi, Mulla, Mulla, Muntean, Oliver, Paden, Park, Perkins, Peters, Pettignano, Phillips, Pieri, Potter, Preston, Protti, Ranucci, Riker, Roberts, Roos, Rosen, Ruiz, Rybak, Saini, Sanfilippo, Satyapriya, Schmith, Shekar, Shekar, Shekar, Shekar, Shekar, Sherwin, Sklar, Smith, Spriet, Staudacher, Strunk, Subramaniam, Szefner, Tellor, Trudzinski, Tulman, Turner, Veinstein, Vilay, Wagner, Walter K. Kraft, Welsch, Wen, Wildschut, Wu, Young   +99 more
core   +2 more sources

Meropenem use and therapeutic drug monitoring in clinical practice: a literature review

Journal of Clinical Pharmacy and Therapeutics, 2021
Meropenem, a carbapenem antibiotic, is widely prescribed for the treatment of life‐threatening infections. The main parameter associated with its therapeutic success is the percentage of time that the levels remain above the minimum inhibitory ...
N. A. Steffens, E. Zimmermann, S. M. Nichelle, Natália Brucker   +3 more
semanticscholar   +1 more source

Clinical consequences of antibody formation, serum concentrations, and HLA-Cw6 status in psoriasis patients on Ustekinumab [PDF]

, 2019
Background: Ustekinumab for the treatment of psoriasis is currently administered in a standard dosing regimen. However, some patients tend to benefit from alternative dosing regimens, a step toward personalized medicine.
Busard, Celine, I, Costanzo, Antonio, De Keyser, Eline, Hutten, Barbara A., Lambert, Jo, Lanssens, Sven, Meuleman, Lieve, Spuls, Phyllis, I, van den Reek, Juul M., Zweegers, Jeffrey   +9 more
core   +1 more source

Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug–Drug Interactions

Therapeutic Drug Monitoring, 2020
Background: COVID-19 is a novel infectious disease caused by the severe acute respiratory distress (SARS)-coronavirus-2 (SARS-CoV-2). Several therapeutic options are currently emerging but none with universal consensus or proven efficacy.
L. Elens, L. Langman, D. Hesselink, S. Bergan, D. Moes, M. Molinaro, R. Venkataramanan, F. Lemaitre   +7 more
semanticscholar   +1 more source